EUVIMEDEUVIMED entdecken
Crossref

Blocking somatic repeat expansion and lowering huntingtin by RNAi synergize to attenuate Huntington’s disease pathogenesis in mice

Jillian Belgrad iD, Ashley Summers iD, Christian Landles iD, Jonathan R Greene, Samuel Hildebrand iD, Emily Knox iD, Ellen Sapp iD, Nozomi Yamada, Raymond Furgal iD, Rachael Miller iD, Georgina F Osborne iD, Kathryn Chase iD und 15 weitere

Science Translational Medicine · 2026

DOI: 10.1126/scitranslmed.aea3104 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, 2026. Verfasst von Jillian Belgrad und 26 weiteren Autor:innen. Beteiligte Einrichtung: UMass Chan Medical School, RNA Therapeutics Institute, Worcester, MA 01605, USA. Hauptthemen laut MEDLINE: Huntington Disease, Huntingtin Protein, RNA Interference, Trinucleotide Repeat Expansion. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 85 Literaturangaben. Gefördert von: National Institutes of Health, Richard and Susan Smith Family Foundation, CHDI Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Huntington’s disease (HD) is a progressive neurodegenerative disorder with no approved therapies. Despite multiple clinical trials, huntingtin (HTT)–lowering strategies have yet to show meaningful clinical benefit. Both somatic expansion and toxic HTT species are key molecular drivers of HD, yet therapeutic strategies targeting these pathways have never been directly compared or evaluated in combination. Using therapeutic divalent siRNAs, we assessed the long-term impact of silencing MutS homolog 3 (MSH3), a critical regulator of somatic expansion, HTT, or both in Q111 HD mice (>110 CAGs), which develop robust expansion, mutant HTT inclusions, and transcriptional dysregulation by 12 months. Long-term MSH3 silencing blocked somatic expansion, reduced inclusions, and normalized gene expression. HTT silencing alone had a limited effect, whereas combined MSH3/HTT targeting synergistically eliminated inclusions and restored transcriptomic profiles. Parallel treatment in wild-type mice showed no toxicity, supporting the safety of long-term intervention. These findings position somatic expansion as a promising therapeutic target and demonstrate the potential of RNAi-based cosilencing of MSH3 and HTT as a disease-modifying strategy for HD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Huntington DiseaseHuntingtin ProteinRNA InterferenceTrinucleotide Repeat ExpansionAnimalsMutS Homolog 3 ProteinMiceRNA, Small InterferingGene SilencingDisease Models, AnimalHumans

Substanzen

Huntingtin ProteinMutS Homolog 3 ProteinRNA, Small InterferingMsh3 protein, mouseHtt protein, mouse

Autor:innen und Institutionen

  • UMass Chan Medical School, RNA Therapeutics Institute, Worcester, MA 01605, USA.
  • Department of Neurodegenerative Disease and Huntington's Disease Centre, Queen Square Institute of Neurology, UCL, London WC1N 3BG, UK.
  • Rancho Biosciences LLC, San Diego, CA 92127, USA.
  • Massachusetts General Hospital, Mass General Institute for Neurodegenerative Disease (MIND), Charlestown, MA 02129, USA.
  • UMass Chan Medical School, Program in Molecular Medicine, Worcester, MA 01605, USA.
  • Charles River Laboratories Inc., 334 South Street, Shrewsbury, MA 01545, USA.

ORCID-Profile: Jillian Belgrad, Ashley Summers, Christian Landles, Samuel Hildebrand, Emily Knox, Ellen Sapp, Raymond Furgal, Rachael Miller, Georgina F Osborne, Kathryn Chase, Jason Freedman, Nicholas McHugh, Daniel O'Reilly, Gillian P Bates, Thomas F Vogt, David Howland, Marian DiFiglia, Neil Aronin, Anastasia Khvorova

Förderung

  • National Institutes of Health
  • Richard and Susan Smith Family Foundation
  • CHDI Foundation

Zitieren

APA

Belgrad, J., Summers, A., Landles, C., Greene, J. R., Hildebrand, S., Knox, E., Sapp, E., Yamada, N., Furgal, R., Miller, R., Osborne, G. F., Chase, K., Luu, E., Freedman, J., Bramato, B., McHugh, N., Nnah, I., Benoit, V., O'Reilly, D., …, & Khvorova, A. (2026). Blocking somatic repeat expansion and lowering huntingtin by RNAi synergize to attenuate Huntington’s disease pathogenesis in mice. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aea3104

Vancouver

Belgrad J, Summers A, Landles C, Greene JR, Hildebrand S, Knox E, et al. Blocking somatic repeat expansion and lowering huntingtin by RNAi synergize to attenuate Huntington’s disease pathogenesis in mice. Science Translational Medicine. 2026. doi:10.1126/scitranslmed.aea3104

BibTeX
@article{Belgrad2026,
  author = {Belgrad, Jillian and Summers, Ashley and Landles, Christian and Greene, Jonathan R and Hildebrand, Samuel and Knox, Emily and Sapp, Ellen and Yamada, Nozomi and Furgal, Raymond and Miller, Rachael and Osborne, Georgina F and Chase, Kathryn and Luu, Eric and Freedman, Jason and Bramato, Brianna and McHugh, Nicholas and Nnah, Israel and Benoit, Vicky and O'Reilly, Daniel and Greer, Paul and Bates, Gillian P and Vogt, Thomas F and Lee, Ramee and Howland, David and DiFiglia, Marian and Aronin, Neil and Khvorova, Anastasia},
  title = {Blocking somatic repeat expansion and lowering huntingtin by RNAi synergize to attenuate Huntington’s disease pathogenesis in mice},
  journal = {Science Translational Medicine},
  year = {2026},
  doi = {10.1126/scitranslmed.aea3104}
}
Kostenlos starten →